Kazia Therapeutics Ltd ADR (KZIA) Stock Price, Quote & News

Company Profile

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in South Korea. Its lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase 3 clinical trial, for the treatment of glioblastoma, isocitrate dehydrogenase-mutant glioma, diffuse intrinsic pontine glioma, atypical teratoid/rhabdoid tumor, brain metast...

Industry: Biotechnology

Sector: Healthcare

Phone: 61 2 9472 4101

Website: www.kaziatherapeutics.com

Address:

Three International Towers, Level 24 300 Barangaroo Avenue, Sydney, Australia

LabMan Aug. 2 at 8:12 AM

$KZIA "The transaction.....involves ordinary shares and prefunded warrants without common warrant coverage." Means the right to buy shares at a future date, after paying full price (or a premium, in this case) for shares, without taking specific ownership of the shares, at the time of transaction. Likely these prefunded warrants will have a nominal exercise price of 1 cents. Done this way for a reason, usually for an existing larger shareholder to circumvent the NASDAG 20% ownership rule - or deemed in this case for a new incoming buyer, being very close to breaching the 20% max ownership rule. Also, share volume Friday would suggest the latest ATM offering has been cleared. Clarification / confirmation awaited from the company, as usual in mandatory post filings. The premium paid, is a most rare and strong endorsement. Looking for - hoping for a "name" incoming investor.

1 · Reply

Moneymastermind99 Aug. 1 at 3:09 PM

🔥 Biotech Bounce Watch: $KZIA + Runners 🔥 $KZIA cooling at $7.83 after wild $11 spike. Low float + clinical pipeline = prime squeeze setup. Watching $8.50 reclaim → $10+, then $13–$15 PT range. 🧬 Also on radar: • $MBOT – stealthy low float robot runner • $BIVI – Alzheimer’s breakout chart, heavy vol • $TCRT – CAR-T sleeper, $2.50 trigger level • $BCLI – squeeze risk w/ FDA noise building These aren’t lotto tickets—these are volatile, catalyst-loaded setups. Tight risk, big moves. #Biotech #KZIA #MBOT #BIVI #Momentum #LowFloat #SqueezeWatch

0 · Reply

Stock_Catcher Aug. 1 at 2:46 PM

$KZIA low float bio getting some flow

1 · Reply

Moneymastermind99 Aug. 1 at 2:30 PM

🚨 $KZIA + Biotech Low Floats on Watch 🔬🔥 $KZIA trading at $7.83, down today but still hot after hitting $11+. Low float + volume = squeeze fuel. Watching for bounce to $9.50+, then $13–$15 targets. 💥 Similar setups: • $MBOT – Robotics runner, ultra low float • $BIVI – Alzheimer’s play w/ breakout chart • $TCRT – CAR-T setup, eyeing $3+ • $BCLI – FDA rumors, low float mover All low float. All high risk/reward. All on squeeze watch. Not financial advice — just sharing setups. #KZIA #LowFloat #BiotechStocks #ShortSqueeze #DayTrading

0 · Reply

Moneymastermind99 Aug. 1 at 2:21 PM

$KZIA

0 · Reply

PT3 Aug. 1 at 2:11 PM

$KZIA why buy more now?

1 · Reply

PT3 Aug. 1 at 1:45 PM

$KZIA bought me some more.

0 · Reply

MC_Money Aug. 1 at 1:17 PM

$KZIA Very nice two reverse splits to screw investors. Then create more stock and watch it tumble again. The turd is WORTHLESS.

1 · Reply

LionsBlaze Aug. 1 at 1:07 PM

$KZIA guess I’m here until news now lol

1 · Reply

gaboriar Aug. 1 at 12:23 PM

$KZIA why would she spike on this? Big volume too. Krazy kazia stock price doing Krazy shit as usual. $3 or $13 today? Why? No reason.

0 · Reply

Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market

Jul 9, 2025, 8:00 AM EDT - 25 days ago

Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial

Jun 11, 2025, 8:00 AM EDT - 7 weeks ago

Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC)

Jun 5, 2025, 8:00 AM EDT - 2 months ago

Kazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer

May 15, 2025, 8:00 AM EDT - 2 months ago

Kazia Therapeutics Highlights Recent Progress and Provides Business Update

Mar 31, 2025, 7:30 AM EDT - 4 months ago

Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil

Jan 30, 2025, 7:30 AM EST - 6 months ago

Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer

Jan 14, 2025, 4:00 PM EST - 7 months ago

Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct Offering

Jan 10, 2025, 9:58 AM EST - 7 months ago

Kazia Therapeutics Announces $2.0 Million Registered Direct Offering

Dec 31, 2024, 12:34 PM EST - 7 months ago

Why Is Brain Cancer-Focused Kazia Therapeutics Stock Trading Lower On Tuesday?

Dec 31, 2024, 8:00 AM EST - 7 months ago

Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA

Dec 11, 2024, 8:00 AM EST - 8 months ago

Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium

Nov 4, 2024, 7:30 AM EST - 9 months ago

Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme

Oct 2, 2024, 8:45 AM EDT - 10 months ago

Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society for Radiation Oncology 66th Annual Meeting

Sep 23, 2024, 8:30 AM EDT - 11 months ago

Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium

Sep 12, 2024, 7:30 AM EDT - 11 months ago

KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER

Jul 10, 2024, 12:24 PM EDT - 1 year ago

Kazia Therapeutics Shares Are Jumping Today: Successful Study For Brain Cancer Treatment

Jul 10, 2024, 7:30 AM EDT - 1 year ago

Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma

Jun 27, 2024, 8:15 AM EDT - 1 year ago

KAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCER

May 23, 2024, 2:41 PM EDT - 1 year ago

Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement

May 1, 2024, 8:45 AM EDT - 1 year ago

KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS

Mar 21, 2024, 8:52 AM EDT - 1 year ago

Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases

Mar 13, 2024, 8:00 AM EDT - 1 year ago

Kazia announces presentation of new data at AACR Annual Meeting

Feb 21, 2024, 7:30 AM EST - 1 year ago

Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint

Jan 18, 2024, 7:30 AM EST - 1 year ago

KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS

Dec 5, 2023, 6:02 PM EST - 1 year ago

Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering

Dec 1, 2023, 8:00 AM EST - 1 year ago

Kazia Therapeutics Announces $2 Million Registered Direct Offering

Nov 29, 2023, 7:01 AM EST - 1 year ago

KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGY

Nov 21, 2023, 7:30 AM EST - 1 year ago

KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING

Nov 20, 2023, 4:30 PM EST - 1 year ago

KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION

Nov 15, 2023, 8:30 AM EST - 1 year ago

KAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING

Nov 10, 2023, 7:01 AM EST - 1 year ago

KAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS HIGHLIGHTING PAXALISIB PRECLINICAL DATA IN MELANOMA

Nov 1, 2023, 7:01 AM EDT - 1 year ago

KAZIA THERAPEUTICS PROVIDES PRELIMINARY UPDATE FROM ONGOING PHASE 2 STUDY OF PAXALISIB IN PRIMARY CNS LYMPHOMA

Oct 23, 2023, 7:01 AM EDT - 1 year ago

KAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM ONGOING PHASE 1 EVT801 STUDY

Oct 11, 2023, 7:01 AM EDT - 1 year ago

Kazia announces voluntary delisting from ASX

Oct 5, 2023, 7:01 AM EDT - 1 year ago

KAZIA THERAPEUTICS ANNOUNCES PRESENTATIONS AT UPCOMING SCIENTIFIC MEETINGS

Sep 29, 2023, 7:01 AM EDT - 2 years ago

KAZIA THERAPEUTICS ANNOUNCES ACCEPTANCE OF LATE-BREAKING ABSTRACT AND ORAL PRESENTATION OF PNOC022 CLINICAL DATA AT 2023 SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING

Jul 6, 2023, 7:00 AM EDT - 2 years ago

KAZIA'S PAXALISIB RECEIVES FAST TRACK DESIGNATION FROM FDA FOR TREATMENT OF SOLID TUMOR BRAIN METASTASES HARBORING PI3K PATHWAY MUTATIONS IN COMBINATION WITH RADIATION THERAPY

Jun 8, 2023, 7:00 AM EDT - 2 years ago

KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA

May 25, 2023, 7:01 AM EDT - 2 years ago

KAZIA CEO, DR. JOHN FRIEND TO PARTICIPATE IN WHITE HOUSE CANCER MOONSHOT

Apr 14, 2023, 7:01 AM EDT - 2 years ago

KAZIA REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

Apr 4, 2023, 7:00 AM EDT - 2 years ago

KAZIA PRESENTS NEW DATA FOR PAXALISIB AND EVT801 AT AACR ANNUAL MEETING

Jan 16, 2023, 7:01 AM EST - 2 years ago

KAZIA RAISES A$4.5 MILLION TO PROGRESS R&D PROGRAMS

Dec 19, 2022, 9:00 PM EST - 2 years ago

Kazia Therapeutics (KZIA): Collaboration May Expand Utility to Combo Therapies

Dec 15, 2022, 7:01 AM EST - 2 years ago

KAZIA LAUNCHES PRECLINICAL COLLABORATION WITH QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE AND ANNOUNCES PATENT FILING

Dec 9, 2022, 5:40 AM EST - 2 years ago

Kazia Therapeutics (KZIA): EVT801 Data Published in Peer-Reviewed Journal

Dec 1, 2022, 7:01 AM EST - 2 years ago

COMPELLING PRECLINICAL DATA FOR KAZIA'S EVT801 PUBLISHED IN PEER-REVIEWED CANCER RESEARCH JOURNAL

Nov 9, 2022, 7:00 AM EST - 2 years ago

KAZIA TO PRESENT PAXALISIB DATA IN ADULT AND PEDIATRIC BRAIN CANCER AT SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING

Nov 2, 2022, 7:10 AM EDT - 2 years ago

Kazia Therapeutics (KZIA): Q123 Cash Flows in Line with Our Estimates

Oct 27, 2022, 7:00 AM EDT - 3 years ago

KAZIA'S PAXALISIB DEMONSTRATES POSITIVE MONOTHERAPY EFFICACY SIGNALS IN PRECLINICAL MODELS OF MELANOMA

LabMan Aug. 2 at 8:12 AM

1 · Reply

Moneymastermind99 Aug. 1 at 3:09 PM

0 · Reply

Stock_Catcher Aug. 1 at 2:46 PM

$KZIA low float bio getting some flow

1 · Reply

Moneymastermind99 Aug. 1 at 2:30 PM

0 · Reply

Moneymastermind99 Aug. 1 at 2:21 PM

$KZIA

0 · Reply

PT3 Aug. 1 at 2:11 PM

$KZIA why buy more now?

1 · Reply

PT3 Aug. 1 at 1:45 PM

$KZIA bought me some more.

0 · Reply

MC_Money Aug. 1 at 1:17 PM

$KZIA Very nice two reverse splits to screw investors. Then create more stock and watch it tumble again. The turd is WORTHLESS.

1 · Reply

LionsBlaze Aug. 1 at 1:07 PM

$KZIA guess I’m here until news now lol

1 · Reply

gaboriar Aug. 1 at 12:23 PM

$KZIA why would she spike on this? Big volume too. Krazy kazia stock price doing Krazy shit as usual. $3 or $13 today? Why? No reason.

0 · Reply

ObsOlet Aug. 1 at 12:22 PM

$KZIA https://www.stocktitan.net/news/KZIA/kazia-therapeutics-announces-2-million-private-placement-at-premium-x3iyd9nfw2bu.html "...This capital injection appears timed to bridge the company to specific data readouts that could potentially enable larger, more favorable financing rounds if positive. The premium pricing suggests the participating institutional investors see value beyond current market valuation. However, the modest size indicates this is likely a bridge financing rather than a comprehensive solution to long-term capital needs, as clinical-stage oncology programs typically require substantially more capital to reach completion."

1 · Reply

Nono22 Aug. 1 at 12:21 PM

$KZIA

0 · Reply

DonCorleone77 Aug. 1 at 12:19 PM

$KZIA Kazia Therapeutics announces $2M private placement

0 · Reply

Stock_Catcher Aug. 1 at 12:17 PM

$KZIA nice dip here had news earlier. 1 m float

0 · Reply

buttermeupalready Aug. 1 at 12:12 PM

$KZIA offering with warrants

1 · Reply

ahTony Aug. 1 at 12:12 PM

$KZIA news out

0 · Reply

fastmoneytraders Aug. 1 at 12:11 PM

shorted $KZIA 10.52 covered 9.24 BAM BABY!!!!!!

0 · Reply

BigSqueezeComing Aug. 1 at 12:11 PM

$KZIA This PIPE at a premium is a noteworthy validation for Kazia’s core assets, especially paxalisib and EVT801. Although $2 million is not a large sum in biotech development terms, it helps the company maintain momentum through upcoming catalyst-rich periods—particularly additional breast cancer trial data.

0 · Reply

trader_1982 Aug. 1 at 12:09 PM

$KZIA $7

0 · Reply

Eventinvestor Aug. 1 at 12:09 PM

$KZIA I like this 👀

0 · Reply

BigSqueezeComing Aug. 1 at 12:08 PM

$KZIA next stop 10.15

0 · Reply

ShhhhImTrading Aug. 1 at 12:08 PM

$KZIA offering at premium to the market

1 · Reply

Market Cap	8.24M
Revenue (ttm)	1.63M
Net Income (ttm)	-17.56M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,077.30%
Debt to Equity Ratio	-0.04

Volume	936,400
Avg Vol	1,334,556
Day's Range	N/A - N/A
Shares Out	1.01M
Stochastic %K	26%
Beta	2.64
Analysts	Strong Sell
Price Target	$14.00